Southeast Asia Breast Cancer Therapeutics Market 2022 Southeast Asia Breast Cancer Therapeutics Market | 页面 5

2.6 Diagnosis 16
2.7 Prognosis and Disease Staging 18
2.8 Treatment Options 20
2.8.1 Surgery and Radiation Therapy 20
2.8.2 Chemotherapy 21
2.8.3 Hormonal Therapies 21
2.8.4 Targeted Therapies 22
2.9 Treatment Guidelines 23
3 Marketed Products 26
3.1 Overview 26
3.1.1 Herceptin (trastuzumab) - Genentech 27
3.1.2 Perjeta (pertuzumab) - Genentech 28
3.1.3 Afinitor (everolimus) - Novartis 29
3.1.4 Tykerb/Tyverb (lapatinib ditosylate monohydrate) - Novartis 30
3.1.5 Ibrance (palbociclib) - Pfizer 30
3.1.6 Ixempra (ixabepilone) - R-Pharm 31
3.1.7 Halaven (eribulin mesylate) - Eisai 32
3.1.8 Avastin (bevacizumab) - Genentech 32
3.1.9 Kadcyla (ado-trastuzumab emtansine) - Genentech 33
3.2 Comparative Efficacy and Safety of Marketed Products 34
4 Pipeline Analysis 40
4.1 Overview 40
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
40
Follow Us: